"Medicamentele AINS care inhiba ciclooxigenaza si biosinteza prostaglandinelor nu compromit RFG la indivizii sanatosi dar pot precipita azotemia prerenala la pacientii cu depletie de volum sau la cei cu insuficienta renala cronica la care RFG este mentinuta in parte prin hiperfiltrarea mediata de prostaglandine datorita nefronilor ramasi functionali." (pg. 1658)
"NSAIDs do not compromise GFR in healthy individuals but may precipitate prerenal ARF in patients with volume depletion or in those with chronic renal insufficiency in whom GFR is maintained, in part, through prostaglandin-mediated hyperfiltration by the remaining functional nephrons."
"Totusi, nu mai putin de 20-30% din pacientii cu IRA ischemica sau nefrotoxica nu au semne evidente clinic sau morfologic de necroza tubulara, subevaluand rolul afectiunii subletale asupra epiteliului tubular si asupra altor celule renale (respectiv celulele endoteliale) in fiziopatologia acestui sindrom. " (pg. 1658)
"However, as many as 20 to 30% of patients with ischemic or nephrotoxic ARF do not have clinical (granular or tubular cell urinary casts) or morphologic evidence of tubular necrosis, underscoring the role of sublethal injury to tubular epithelium and injury to other renal cells (e.g., endothelial cells) in the pathophysiology of this syndrome."
miercuri, 24 octombrie 2007
Abonați-vă la:
Postare comentarii (Atom)
Niciun comentariu:
Trimiteți un comentariu